About VYNE Therapeutics Inc.
https://www.vynetherapeutics.comVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
CEO
David T. Domzalski
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-13 | Reverse | 1:18 |
| 2021-02-16 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:851.35K
Value:$482.38K
DSC ADVISORS, L.P.
Shares:696.47K
Value:$394.62K
ACORN CAPITAL ADVISORS, LLC
Shares:586.57K
Value:$332.35K
Summary
Showing Top 3 of 39
About VYNE Therapeutics Inc.
https://www.vynetherapeutics.comVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $169K ▲ | $7.96M ▲ | $-7.28M ▼ | -4.31K% ▲ | $-0.17 ▼ | $-7.42M ▲ |
| Q2-2025 | $69K ▼ | $7.61M ▼ | $-5.75M ▲ | -8.34K% ▼ | $-0.13 ▲ | $-7.54M ▲ |
| Q1-2025 | $202K ▲ | $9.4M ▼ | $-8.61M ▲ | -4.26K% ▲ | $-0.2 ▲ | $-9.19M ▲ |
| Q4-2024 | $84K ▼ | $12.85M ▼ | $-12.02M ▲ | -14.31K% ▼ | $-0.28 ▲ | $-12.77M ▲ |
| Q3-2024 | $121K | $13.21M | $-12.16M | -10.05K% | $-0.29 | $-13.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $32.7M ▼ | $36.13M ▼ | $4.04M ▼ | $32.09M ▼ |
| Q2-2025 | $39.65M ▼ | $44.72M ▼ | $5.84M ▼ | $38.88M ▼ |
| Q1-2025 | $50.27M ▼ | $56.42M ▼ | $12.29M ▼ | $44.13M ▼ |
| Q4-2024 | $61.52M ▼ | $66.91M ▼ | $14.82M ▲ | $52.09M ▼ |
| Q3-2024 | $70.19M | $76.2M | $12.66M | $63.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.28M ▼ | $-7.1M ▲ | $4.4M ▼ | $-7K ▲ | $-2.7M ▲ | $-7.1M ▲ |
| Q2-2025 | $-5.75M ▲ | $-10.8M ▲ | $4.67M ▼ | $-34K ▲ | $-6.16M ▼ | $-10.8M ▲ |
| Q1-2025 | $-8.61M ▲ | $-11.46M ▼ | $19.83M ▲ | $-87K ▲ | $8.28M ▲ | $-11.46M ▼ |
| Q4-2024 | $-12.02M ▲ | $-9M ▼ | $12.74M ▲ | $-132K ▼ | $3.61M ▲ | $-9.12M ▼ |
| Q3-2024 | $-12.16M | $-8.51M | $-4.82M | $-2K | $-13.34M | $-8.51M |
Revenue by Products
| Product | Q4-2022 | Q1-2023 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David T. Domzalski
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-13 | Reverse | 1:18 |
| 2021-02-16 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:851.35K
Value:$482.38K
DSC ADVISORS, L.P.
Shares:696.47K
Value:$394.62K
ACORN CAPITAL ADVISORS, LLC
Shares:586.57K
Value:$332.35K
Summary
Showing Top 3 of 39